Ken Griffin Arca Biopharma, Inc. Put Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Put Options

5 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$1.71 - $4.0 $9,576 - $22,400
5,600 New
5,600 $21,000
Q3 2023

Nov 14, 2023
BUY
$2.01 - $2.07 $200 - $206
100 New
100 $0
Q1 2023

May 15, 2023
BUY
$1.99 - $2.55 $7,761 - $9,945
3,900 Added 114.71%
7,300 $14,000
Q4 2022

Feb 14, 2023
SELL
$1.86 - $25.8 $25,110 - $348,300
-13,500 Reduced 79.88%
3,400 $8,000
Q3 2022

Nov 14, 2022
SELL
$2.13 - $25.68 $70,716 - $852,576
-33,200 Reduced 66.27%
16,900 $35,000

Others Institutions Holding ABIO

# of Institutions
2
Shares Held
280K
Call Options Held
0
Put Options Held
0
View Full List

About ARCA biopharma, Inc.

ABIO Quotes by TradingView
  • Ticker ABIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,410,100
  • Description
  • ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydr...
More about ABIO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email